AstraZeneca has confirmed that it has filed a lawsuit in the U.S. District Court for the District of Delaware against the generic company Andrx for patent infringement.The lawsuit is th
PRB Pharmaceuticals and Lee's Pharmaceuticals have announced the discovery that PRB'S patent pending botanical extract, V38-AMF-1, comp
Last tuesday marked the conclusion of a patent trial involving discontinued trocar products by United States Surgical, a market leader and innovator of minimally invasive surgical instruments.Following an earlier February 2002 infringement ruli
Zyomyx a privately held biotechnology company, has announced that the United States Patent and Trademark Office issued five new patents to the Company. With these additions, Zyomyx has further strength
Cyntellect a privately-held biotechnology company, has announced the issuance of U.S. Patent No. 6,753,161 covering the Company's LaserFect(TM) technology.LaserFect represents the first tec
The Institute of Cancer Research and Cancer Research Technology Limited, the technology transfer company of the charity
United States Federal Judge Paul G. Cassell granted Hema Metrics' motion for Summary Judgment on the issue of infringement for all inventions. In the ruling, the court concluded that Hema
StemCells, Inc. has announced that the Company has been issued U.S. patent 6,777,233 for work done at the Company covering composition of matter claims for the human neural stem cell."Thi
Body tissues such as blood vessels, cartilage and skin - even whole organs such as kidneys, livers and hearts - could become more widely available for transplants as a result of a patent issued recently to Organ Recovery Systems of Chicago for a method
FMD has announced it has been granted patent 6,780,161. Issued on August 24, 2004, the patent covers the new technology of Twinheads(R) which uses two or more shock wave sources in the extracorp
Genaissance developed this technology, the DecoGen(R) Informatics System, with the goal of reducing adverse events and increasing positive outcomes of broadly used medicines through more informed prescribing decisions. The allowed patent claims specifically cover novel haplotype correlation methods for identifying drug safety and efficacy markers as well as disease susceptibility markers.
The DecoGen(R) Informatics System combines a comprehensive database of genetic variation information with a set of computer applications for storing and analyzing genetic variation, especially in the context of pharmacogenetic clinical trials. The Company expects that the patent, titled "Methods for Obtaining and Using Haplotype Data," will issue in the first half of 2005.
The DecoGen(R) system is a key component in Genaissance's Phase II pharmacogenetic development plans for vilazodone, an antidepressant drug candidate recently licensed from Merck KGaA, and also in the fulfillment of obligations in support of clinical trials with its pharmaceutical and biopharmaceutical partners.
"DecoGen(R)'s throughput and accuracy have established it as an important technology for discovering genetic variables that are likely to interfere with a drug's intended features," notes Kevin Rakin, President and Chief Executive Officer of Genaissance. "This knowledge can be of immense value to physicians in their current prescribing patterns and may also help in the reformulation of drugs to avoid adverse events."
"Our unique informatics-intensive approach of utilizing haplotype-based association methods has increased our ability to identify genetic markers of clinical significance. Recently published results from STRENGTH and data from CARING have identified haplotype markers of drug response (both efficacy and safety) that are of greater specificity and sensitivity than have previously been discovered using standard pharmacogenetic association methods," stated Richard Judson, Ph.D., Chief Scientific Officer of Genaissance.
Genaissance has patent applications pending that cover other methods within the DecoGen(R) Informatics System, including Genaissance's HAP(TM) Builder software, which builds haplotypes with high accuracy from genotypes for multiple single nucleotide polymorphisms (SNPs) in a gene.
http://www.genaissance.com/